MRG domain binding protein (MRGBP)

MRG domain binding protein (MRGBP) is a conserved subunit of the NuA4 (TRRAP/TIP60) histone acetyltransferase complex essential for chromatin remodeling, transcriptional regulation, and DNA repair[3][5]. It binds directly to proteins such as MRG15 and MRGX and orchestrates multiprotein assemblies implicated in acetylation of histones H4 and H2A, thereby promoting transcriptional activation and participating in the regulation of cell cycle, DNA replication, and double-strand break repair via homologous recombination[2][5]. MRGBP expression is low in most normal tissues but upregulated in various cancers, where it promotes cell proliferation, tumor growth, and progression, likely through its effects on chromatin structure and cell cycle gene expression[3][4]. Loss or inhibition of MRGBP leads to alterations in DNA double-strand break repair kinetics and can increase genomic instability, marking it as both a prognostic biomarker and a potential therapeutic target in oncology[2][4][5]. No FDA-approved drugs are known to target MRGBP directly, but its central role in chromatin biology and DNA repair makes it a subject of ongoing research for cancer therapy development.

Other names

MRG/MORF4L-binding proteinC20orf20Urcc4FLJ10914MRG15BPEaf7Up-regulated in colon cancer 4URCC4MRG-binding protein

Not directly targeted by approved drugs; considered a potential future therapeutic target, particularly via modulation of chromatin remodeling or inhibition of the NuA4 complex[3][4]